NCT00000687View on ClinicalTrials.gov

Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 1993

Conditions

Sarcoma, KaposiHIV Infections

Interventions

DRUG

Interferon alfa-2a

DRUG

Zidovudine

Trial Locations (9)

10003

Beth Israel Med. Ctr. (Mt. Sinai), New York

21287

Johns Hopkins Adult AIDS CRS, Baltimore

33136

Univ. of Miami AIDS CRS, Miami

43210

The Ohio State Univ. AIDS CRS, Columbus

44106

Case CRS, Cleveland

02215

Beth Israel Deaconess - East Campus A0102 CRS, Boston

Unknown

Washington U CRS, St Louis

Univ. of Rochester ACTG CRS, Rochester

Pitt CRS, Pittsburgh

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000687 - Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma | Biotech Hunter | Biotech Hunter